目的 分析2013—2017年天津市肿瘤医院抗生素类抗肿瘤药物的使用情况。方法 调取天津市肿瘤医院2013—2017年抗生素类抗肿瘤药物的相关用药信息，对使用金额、用药频度（DDDs）、日均费用（DDC）及药品排序比（B/A）进行统计与分析。结果 2013—2016年，抗生素类抗肿瘤药物的总销售金额呈增长趋势，2017年有所回落。表柔比星、吡柔比星和伊达比星的销售金额连续排名前3位。2013—2017年，DDDs大部分有所增长。吡柔比星和表柔比星的持续位于前两位，绝大多数抗生素DDDs的排序基本稳定。2013—2016年，除放线菌素D的DDC增长幅度比较大外，其他抗生素类抗肿瘤药物的DDC比较平稳。2017年DDC值均下降，排序相对稳定，伊达比星的DDC持续居于首位，超过600元，其他药物DDC均在100元以下。2013—2017年，B/A值在1上下浮动，表明大多数药物使用金额与使用频度同步性较好。结论 天津市肿瘤医院抗生素类抗肿瘤药物的使用基本合理，符合安全、有效、经济、方便的原则。

Objective To analyze the utilization of antibiotic anti-tumor drugs in Tianjin Cancer Hospital from 2013 to 2017. Methods The utilization information of antibiotic anti-tumor drugs in Tianjin Cancer Hospital from 2013 to 2017 was extracted, and the consumption sum, defined daily doses (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) were analyzed statistically. Results From 2013 to 2016, the total consumption sums of antibiotic anti-tumor drugs were increased, and were decreased in 2017. Consumption sums of pirarubicin, epirubicin, and idarubicin were ranked in the top 3 for five years. Most of DDDs showed a declining tendency in five years. Pirarubicin and epirubicin occupied the front two positions. In addition to actinomycin D DDC increasing fast, DDC of the other antibiotic anti-tumor drugs were relatively stable. In 2017, the DDC values were all decreased and the ranking was relatively stable. DDC of idarubicin was in the first place, and was more than 600 yuan, and DDC of others were all below 100 yuan. B/A of most antibiotic anti-tumor drugs were close to 1.00, indicating that the synchronism of the consumption and the frequency was acceptable. Conclusion The utilization of antibiotic anti-tumor drugs in Tianjin Cancer Hospital is reasonable on the whole, according with the principle of safety, effectiveness, economy, and convenience.